Compare Cardinal Health Inc (CAH) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Las Vegas Sands Corp. — how do they compare? Cardinal Health Inc trades at $228.96 (market cap $53.89B), while Las Vegas Sands Corp. trades at $44.65 (market cap $29.67B). The key difference: Cardinal Health Inc is the larger of the two by market cap, and Las Vegas Sands Corp. pays the higher dividend (2.46%). Which is the better fit depends on your goals.
| CAH | LVS | |
|---|---|---|
Market Cap | $53.89B | $29.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $239.71 | $69.49 |
52-Week Low | $146.04 | $44.78 |
Enterprise Value | $58.87B | $42.07B |
Dividend Yield | 0.89% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
LVS trades at $45.90, down 1.69% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 revenue of $3.59 billion, up 25.3% year-over-year, and EPS of $0.91, beating estimates. Analyst consensus is strongly bullish with a $65.56 price target, though technical indicators show selling pressure near key support at $45.
LVS presents a compelling value opportunity with a P/E of 16.94 and consistent earnings beats, but faces headwinds from high debt levels and bearish technical momentum. Upside potential exists if the stock holds support and executes on growth, while downside risk persists if macroeconomic or regulatory pressures intensify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
